How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis

Eleftheria Hatzimichael, Nel Syed, Cristiana Lo Nigro, Bhavya Rao, Tim Crook (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Detection in blood of the genetic and epigenetic changes present in metastatic cancers is opening up new possibilities in molecular diagnostics. A number of methodological and clinical issues await resolution before serum epigenetic biomarkers can be considered a routine part of the management of melanoma patients following primary excision. However, there is every possibility that blood testing for the presence of methylated DNA will become an integral part of the clinical follow-up of such patients. The ability to identify patients with subclinical (asymptomatic) metastatic melanoma, combined with new, highly active targeted and immunomodulatory agents, may lead to further improvements in outcomes for this patient population.
    Original languageEnglish
    Pages (from-to)639-642
    Number of pages4
    JournalExpert Review of Molecular Diagnostics
    Volume14
    Issue number6
    Early online date13 Jun 2014
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis'. Together they form a unique fingerprint.

  • Cite this